The nuclear-factor ?B (NF-?B) family of transcription factors plays a central role in regulating many physiological processes including innate and adaptive immunity. In addition, accumulating evidence suggests that inappropriate activation of NF-?B occurs in many types of human cancers. Although genetic alterations of specific core components of the NF-?B signaling pathway have been identified in a few lymphoid malignancies, the molecular alterations that lead to and the consequences of increased NF-:B activity in the pathogenesis of human cancers remain incompletely understood. In recent work, we have identified the inhibitor of ?B kinase 5 (IKBKE, IKKi IKK5) as amplified and overexpressed in a substantial subset of human breast cancer cell lines and tumors. IKK5 is required for the survival of breast cancer cell lines that harbor IKK5 copy number gain and confers a tumorigenic phenotype when expressed in immortalized human mammary epithelial cells. Breast cancer cell lines and tumors that overexpress IKK5 exhibit increased NF-?B activity, which is essential for their transformed phenotype. These observations classify IKK5 as a breast cancer oncogene and may also explain the increased NF-?B activity previously described in a subset of human breast cancers. Based on these observations, this proposal focuses on investigating the role of IKK5 in breast cancer pathogenesis. Specifically, biochemical, genetic and molecular biological approaches will be applied to identify and characterize which substrates and interacting proteins of this non-canonical IKK are critical for tumorigenicity, to investigate how ubiquitination regulates IKK5 activity and function in breast cancer and to dissect the roles of IKK5 in tumor initiation and maintenance in genetically engineered mice. Investigating the regulation and function of IKK5 in breast cancer development will not only enhance our mechanistic understanding of this non-canonical IKK regulator but will also clarify the role of NF-?B signaling in the development of human epithelial cancers. In addition, these studies will provide a foundation for strategies to target this kinase oncogene therapeutically.

Public Health Relevance

Although significant progress has been made in the diagnosis and treatment of breast cancer, we lack curative targeted therapies for many advanced stage breast cancers. This proposal focuses on deciphering the role of a newly discovered oncogene in breast cancer initiation and maintenance. These biochemical, cell and animal-based studies will not only provide insight into the biology of this kinase oncogene but will serve as a foundation for translational studies for the development of novel therapeutic agents.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA130988-05
Application #
8408801
Study Section
Cancer Molecular Pathobiology Study Section (CAMP)
Program Officer
Yassin, Rihab R,
Project Start
2009-03-01
Project End
2014-12-31
Budget Start
2013-01-01
Budget End
2014-12-31
Support Year
5
Fiscal Year
2013
Total Cost
$313,646
Indirect Cost
$124,447
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Moody, S E; Schinzel, A C; Singh, S et al. (2015) PRKACA mediates resistance to HER2-targeted therapy in breast cancer cells and restores anti-apoptotic signaling. Oncogene 34:2061-71
Zhu, Zehua; Aref, Amir R; Cohoon, Travis J et al. (2014) Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit. Cancer Discov 4:452-65
Zhou, Alicia Y; Shen, Rhine R; Kim, Eejung et al. (2013) IKKýý-mediated tumorigenesis requires K63-linked polyubiquitination by a cIAP1/cIAP2/TRAF2 E3 ubiquitin ligase complex. Cell Rep 3:724-33
Serra, Violeta; Eichhorn, Pieter J A; Garcia-Garcia, Celina et al. (2013) RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer. J Clin Invest 123:2551-63
Shrestha, Y; Schafer, E J; Boehm, J S et al. (2012) PAK1 is a breast cancer oncogene that coordinately activates MAPK and MET signaling. Oncogene 31:3397-408
Shen, R R; Hahn, W C (2011) Emerging roles for the non-canonical IKKs in cancer. Oncogene 30:631-41
Kim, So Young; Dunn, Ian F; Firestein, Ron et al. (2010) CK1epsilon is required for breast cancers dependent on beta-catenin activity. PLoS One 5:e8979
Hutti, Jessica E; Shen, Rhine R; Abbott, Derek W et al. (2009) Phosphorylation of the tumor suppressor CYLD by the breast cancer oncogene IKKepsilon promotes cell transformation. Mol Cell 34:461-72
Downward, Julian; Hahn, William C (2009) Genetic and cellular mechanisms of oncogenesis. Curr Opin Genet Dev 19:1-3
Barbie, David A; Tamayo, Pablo; Boehm, Jesse S et al. (2009) Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462:108-12